AVN-101
AVN-101
AVN-101 (pronounced: A-V-N-One-Zero-One) is a novel, multi-target drug candidate developed by Avena Pharmaceuticals. It is primarily used in the treatment of neurodegenerative diseases and mental disorders.
Etymology
The term "AVN-101" is derived from the name of the pharmaceutical company, Avena, that developed the drug, and the number 101, which is a unique identifier for the drug candidate within the company's portfolio.
Usage
AVN-101 is a potent antagonist for serotonin receptors, specifically 5-HT6, 5-HT7, and 5-HT2A. It also exhibits high affinity to sigma-2 receptors and moderate affinity to sigma-1 receptors. This makes it a potential candidate for the treatment of various neurodegenerative diseases and mental disorders, including Alzheimer's disease, schizophrenia, and depression.
Related Terms
- Neurodegenerative diseases: A variety of conditions which primarily affect the neurons in the human brain.
- Serotonin receptors: A group of G protein-coupled receptors and ligand-gated ion channels found in the central and peripheral nervous systems.
- Alzheimer's disease: A chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. It is the cause of 60–70% of cases of dementia.
- Schizophrenia: A mental disorder characterized by continuous or relapsing episodes of psychosis.
- Depression: A mental health disorder characterized by persistently depressed mood or loss of interest in activities, causing significant impairment in daily life.
External links
- Medical encyclopedia article on AVN-101
- Wikipedia's article - AVN-101
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski